Charles River Laboratories International (NYSE:CRL) Updates FY25 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $9.10-$9.60 for the period, compared to the consensus earnings per share estimate of $9.60. The company issued revenue guidance of $3.77-$3.87 billion, compared to the consensus revenue estimate of $3.87 billion. Charles River Laboratories International also updated its FY 2025 guidance to 9.100-9.600 EPS.

Charles River Laboratories International Stock Performance

Shares of CRL traded up $0.09 during mid-day trading on Friday, hitting $162.34. 180,010 shares of the company’s stock were exchanged, compared to its average volume of 1,027,646. Charles River Laboratories International has a fifty-two week low of $150.79 and a fifty-two week high of $275.00. The firm has a market capitalization of $8.30 billion, a P/E ratio of 1,082.29, a P/E/G ratio of 6.77 and a beta of 1.37. The business’s 50 day moving average is $173.39 and its two-hundred day moving average is $188.81. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the prior year, the firm earned $2.46 earnings per share. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. On average, equities analysts expect that Charles River Laboratories International will post 9.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Evercore ISI boosted their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. TD Cowen lifted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Robert W. Baird decreased their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $195.71.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).